|
⚲
|
| Keyboard |
| Deep Track Capital LP
✚
|
|
|---|---|
| CRD # | 312459 |
| SEC # | 801-120500 |
| CIK # | 0001856083 |
| AUM | 8,373.4 M (2026-03-31) |
| Employees | 19 (63% Investors, 0% Brokers) |
| Phone | 203-409-0810 |
| Address | 200 Greenwich Avenue Greenwich, CT 06830 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Wed, 15 Jul 2026 | Draig Therapeutics Closes $65M Series B Led by Deep Track Capital — citybiz |
| Tue, 14 Jul 2026 | Attovia Therapeutics Investors Include Deep Track Capital, Frazier Life Sciences, Alamar Biosciences and Goldman Sachs — Moomoo |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Guardant Health Inc | 0.3 | ||
| Health Sciences Acquisitions Corp | 0.3 | ||
| Tarsus Pharmaceuticals Inc | 0.3 | ||
| Vaxcyte Inc | 0.2 | ||
| Structure Therapeutics Inc | 0.2 | ||
| Axsome Therapeutics Inc | 0.2 | ||
| Ocular Therapeutix Inc | 0.2 | ||
| Vera Therapeutics Inc | 0.2 | ||
| Alumis Inc | 0.1 | ||
| ISIS Pharmaceuticals Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Deep Track Special Opportunities Fund LP | 2025-11-19 | 284.6 M | |
| HF | Deep Track Biotechnology Master Fund Ltd | 2021-07-08 | 8,088.7 M |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 8.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 8.4 |
| By Discretionary | ||
| Discretionary | 5 | 8.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 8.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 5.6 | |
| United States Persons | 2.8 | |
| Total | 5 | 8.4 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001856083] | |
| 3 | [0001856083] | |
| 4 | [0001856083] | |
| SC 13D | [0001856083] | |
| SC 13G | [0001856083] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 5493005XI3U41MXN3456 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Dynavax Technologies Corp DVAX
Common Stock, par value $0.001 per share
|
2026-02-10 | Tender | 15,726,349 | ||
|
LB Pharmaceuticals Inc LBRX
Pre-Funded Warrants (Right to Buy) · derivative
|
2026-02-06 | Buy | 93,925 | $21.17 | 1,988,392 |
|
LB Pharmaceuticals Inc LBRX
Pre-Funded Warrants (Right to Buy) · derivative
|
2026-02-06 | Buy | 378,444 | $21.17 | 8,011,659 |
|
Nektar Therapeutics NKTR
Common Stock
|
2024-05-10 | Sell | 56,000 | $1.78 | 99,680 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Eldridge Credit Advisers LLC
✚
|
NY | 8,459.5 M |
|
Vista Credit Partners LP
✚
|
NY | 8,422.8 M |
|
Chatham Asset Management LLC
✚
|
NJ | 8,271.7 M |
|
Aequim Alternative Investments LP
✚
|
CA | 8,248.0 M |
|
Ironwood Capital Management Corp
✚
|
CA | 8,225.8 M |
|
Wincoram Asset Management LLC
✚
|
TX | 8,186.1 M |
|
Starboard Value LP
✚
|
NY | 8,151.9 M |
|
Overlook Investments Limited
✚
|
8,092.8 M | |
|
Overlook Investments LP
✚
|
8,092.8 M | |
|
Context Capital Management LLC
✚
|
CA | 8,008.2 M |